[Evaluation of cardiovascular risk in the cross-sectional phase of the Mediterranean Study].
The Mediterranean study quantifies high cardiovascular risk (HCR), consistency between REGICOR (R) and low risk SCORE (LS) scales, altered blood pressure (ABP) values in hypercholesterolemia (HC) without any history of hypertension (HT), high total cholesterol (HTC) values with HT with no background of HC and cardiac and renal damage in hypertensive patients. A national, cross-sectional and multicenter study was performed with the participation of 751 physicians. The physicians individually evaluated 7,973 patients with HT and 5,319 with HC. HCR was defined as over 10% with R and 5% with LS. Intra-class correlation coefficient (ICC) and Pearson coefficient (r) were calculated. The percentages of ABP and HTC were quantified. Creatinine (cr) value, glomerular filtration rate using Cockroft-Gault (CG), and prevalence of left ventricular hypertrophy (LVH) were analyzed. Regarding hypertensive patients: 17.3% HCR with R and 26.1% with LS. ICC = 0.222 (p < 0.0001), r = 0.61 (p < 0.0001), 64.7% HTC. There was no evaluation of LVH in 31.2% and a prevalence of 5.1%, prevalence of lesion and kidney failure (KF) of 4.7% and 1.6% respectively based on CR and 15.9% KF by CG. In HC patients, there was 21.1% of HCR with R and 21.5% with LS; ICC = 0.190 (p < 0.0001), r = 0.64 (p < 0.0001) and 33.7% ABP. The SCORE scale identifies more patients with HCR than the REGICOR one in HT patients and a similar amount in HC patients. Consistency between both scales is poor. A significant ABP/HTC was found. In HT patients, the patients who were not evaluated for LVH and the percentage of KF are important.